SARS-CoV-2 one year on: evidence for ongoing viral adaptation

Abstract
SARS-CoV-2 is thought to have originated in the human population from a zoonotic spillover event. Infection in humans results in a variety of outcomes ranging from asymptomatic cases to the disease COVID-19, which can have significant morbidity and mortality, with over two million confirmed deaths worldwide as of January 2021. Over a year into the pandemic, sequencing analysis has shown that variants of SARS-CoV-2 are being selected as the virus continues to circulate widely within the human population. The predominant drivers of genetic variation within SARS-CoV-2 are single nucleotide polymorphisms (SNPs) caused by polymerase error, potential host factor driven RNA modification, and insertion/deletions (indels) resulting from the discontinuous nature of viral RNA synthesis. While many mutations represent neutral ‘genetic drift’ or have quickly died out, a subset may be affecting viral traits such as transmissibility, pathogenicity, host range, and antigenicity of the virus. In this review, we summarise the current extent of genetic change in SARS-CoV-2, particularly recently emerging variants of concern, and consider the phenotypic consequences of this viral evolution that may impact the future trajectory of the pandemic.
Funding Information
  • Biotechnology and Biological Sciences Research Council (BB/R013071/1)
  • Medical Research Council (MR/N013840/1)
  • U.S. Food and Drug Administration (75F40120C00085)
  • Wellcome Trust (205100)
  • Biotechnology and Biological Sciences Research Council (BB/K002465/1)
  • Biotechnology and Biological Sciences Research Council (BB/S008292/1)